Geographic atrophy causes retinal degeneration and incurable visual impairment in the elderly. Based on genome-wide association studies and protein stainings in the patient eye, the complement system was described a contributor to disease progression.
Today I updated my knowledge regarding complement targeting therapies for AMD in clinical trials. I share with you my personal notes. I categorized 1st and 2nd generation therapeutics based on the strategy and target protein.
For further readings follow the pubmed IDs (PMID) or the identification code given of ClinicalTrials.gov (NCT).
Diana
Comments